標(biāo)題: Titlebook: Brain Tumor Immunotherapy; Linda M. Liau,Donald P. Becker,Darell D. Bigner Book 2001 Springer Science+Business Media New York 2001 apoptos [打印本頁] 作者: hearken 時間: 2025-3-21 18:37
書目名稱Brain Tumor Immunotherapy影響因子(影響力)
作者: INERT 時間: 2025-3-21 21:53 作者: 時代錯誤 時間: 2025-3-22 01:11 作者: 全等 時間: 2025-3-22 04:44
Biological Principles of Brain Tumor Immunotherapyd the presence of CNS complement, are presented as well, because these areas represent new potential areas for therapeutic intervention. Discussion of application of this information, including manipulation of cytokines, adoptive IT, vaccination, and tumor-specific Ag approaches, is reserved for other chapters.作者: conifer 時間: 2025-3-22 09:32
Book 2001unotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.作者: 信條 時間: 2025-3-22 15:15
Book 2001therapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, and help define the current status of the fie作者: Ischemia 時間: 2025-3-22 17:44 作者: Hyperlipidemia 時間: 2025-3-23 01:13 作者: 壁畫 時間: 2025-3-23 02:15
Systemic T-Cell Immunotherapy for Brain Tumorsafferent immune response (IR) Indeed, early studies using transplantation of allogeneic tissues established the concept of “immune privilege” for the brain .. However, there is ample clinical ., and experimental . evidence that the brain is permissive for T-cell-mediated efferent IRs.作者: Flawless 時間: 2025-3-23 07:10 作者: Texture 時間: 2025-3-23 13:07
ehensive guide to modern brain tumor immunotherapy and thereby enhance future research in this area. The contributors detail many of the key laboratory experiments and clinical protocols that are currently being investigated, integrate the available information from previous and ongoing research, an作者: interior 時間: 2025-3-23 17:24
https://doi.org/10.1007/978-3-031-43427-3 and lack of discrete lymphoid tissue, there are immunocompetent cells within the brain parenchyma. These cells do provide surveillance and also permit the brain to mount an immunologic response in concert with peripheral mechanisms of immunity, which include both cellular and humoral components ..作者: Breach 時間: 2025-3-23 20:39
Efficient Hyperdimensional Computingherapy (IT) strategies became of interest to neuro-oncology researchers, because regeneration of normal brain is considered limited, at best, and because the potential for selectivity in tumor over normal cell destruction is seemingly inherent in the immune system.作者: OFF 時間: 2025-3-23 22:33 作者: 蠟燭 時間: 2025-3-24 02:54 作者: 石墨 時間: 2025-3-24 09:15
Cytotoxic T-Lymphocytes Reactive to Patient Major Histocompatibility Complex Proteins for Therapy ofherapy (IT) strategies became of interest to neuro-oncology researchers, because regeneration of normal brain is considered limited, at best, and because the potential for selectivity in tumor over normal cell destruction is seemingly inherent in the immune system.作者: 同步信息 時間: 2025-3-24 14:13 作者: charisma 時間: 2025-3-24 15:06
ing-edge and comprehensive, Brain Tumor Immunotherapy brings together all the important recent advances in our understanding of central nervous system tumor immunology and illustrates in powerful detail the many new applications now harnessing the immune response for brain tumor therapeutics.978-1-61737-110-3978-1-59259-035-3作者: homocysteine 時間: 2025-3-24 20:14
Yifan Zhao,Xian Yang,Ranga Raju Vatsavaiexplosion of epidemiological and molecular genetic studies of BTs, has focused attention on this important human cancer, which, up until only a few decades ago, was relatively little studied. Despite this surge of interest, the etiology of the majority of nervous system tumors remains unknown. Inher作者: 善辯 時間: 2025-3-25 00:42 作者: conjunctivitis 時間: 2025-3-25 06:04 作者: 沐浴 時間: 2025-3-25 09:50
https://doi.org/10.1007/978-3-031-43412-9when conjugated to a strong protein carrier, such as keyhole limpet hemocyanin (KLH), G. stimulates only a weak IgG response. It is also well known that shed gangliosides (e.g., G.) can inhibit cellular immunity ., partly explaining why ganglioside vaccines may not be an ideal IT approach. Furthermo作者: 責(zé)怪 時間: 2025-3-25 11:50 作者: rods366 時間: 2025-3-25 17:45
Epidemiology of Primary Brain Tumorsexplosion of epidemiological and molecular genetic studies of BTs, has focused attention on this important human cancer, which, up until only a few decades ago, was relatively little studied. Despite this surge of interest, the etiology of the majority of nervous system tumors remains unknown. Inher作者: 輕觸 時間: 2025-3-25 22:14
Current Therapy for Primary Brain Tumorsto the eighth decade of life .,.. The average annual increase in the incidence of primary BTs in elderly patients in the United States, between 1974 and 1985, was 7.0% for the 75-79-yr-old age group, 20.4% in the 80–84 yr age group, and 23.4% in those 85 yr and older. These diagnoses were predominan作者: insert 時間: 2025-3-26 00:56
Autologous Vaccine and Adoptive Cellular Immunotherapy as Treatment for Brain Tumorsi (such as anti-CD3) can activate primed T-lymphocytes to differentiate into Ag-specific effector cells in vitro, and interleukin-2 (IL-2) stimulates these cells to proliferate. Activated effector T-lymphocytes are able to travel to sites of tumor growth, enter and reject the tumor, and potentially 作者: Radiculopathy 時間: 2025-3-26 07:28 作者: preeclampsia 時間: 2025-3-26 09:19
Radiolabeled Antibodies for Therapy of Brain Tumorsxhibited Ab localization as detected by immunoscintigraphy .. Because of the nonspecificity of the target antigen (Ag), as well as the heterogeneous distribution of FIB in tumors, the utility of targeting FIB for diagnostic or therapeutic purposes was concluded to be low. In a series of studies ., D作者: 分解 時間: 2025-3-26 15:52 作者: aggressor 時間: 2025-3-26 19:56 作者: 朋黨派系 時間: 2025-3-26 23:19
Antibodies to Adhesion Molecules for Immunotherapy of Brain Tumorscells. Several adhesion molecules that are downregulated after completion of fetal brain development are re-expressed in neoplasms of the nervous system. The crucial role played by adhesion molecules during neural development is repeated during glioma invasion ..作者: Collision 時間: 2025-3-27 03:06 作者: 不能仁慈 時間: 2025-3-27 09:01 作者: 削減 時間: 2025-3-27 12:24
http://image.papertrans.cn/b/image/190241.jpg作者: Juvenile 時間: 2025-3-27 15:25
https://doi.org/10.1007/978-1-59259-035-3apoptosis; brain; brain tumor; brain tumors; cell; central nervous system; gene therapy; immunotherapy; lymp作者: MORT 時間: 2025-3-27 21:11 作者: Comedienne 時間: 2025-3-28 00:09
Liang Zhang,Shubin Xie,Jianming Dengvelopment, the neuroectoderm surrounding the neural tube gives rise to all of the major intrinsic cell types of the CNS, including neurons and glia. Glia are traditionally subtyped into four major categories: astrocytes, oligodendrocytes, ependymal cells, and microglia. Microglia, even though they a作者: 偶像 時間: 2025-3-28 05:49
Yifan Zhao,Xian Yang,Ranga Raju Vatsavaithese would die from the disease .. When benign as well as malignant brain tumors (BTs) are included, the incidence is over twice that for malignant BTs alone; 34,345 individuals were newly diagnosed with a benign or malignant nervous system tumor in 1998 .. Only about one-half of patients with mali作者: plasma 時間: 2025-3-28 08:45 作者: 鞠躬 時間: 2025-3-28 14:29
https://doi.org/10.1007/978-3-031-43427-3ent experimental evidence suggests that, despite the anatomical segregation of the brain from the general circulation by the blood-brain barrier (BBB) and lack of discrete lymphoid tissue, there are immunocompetent cells within the brain parenchyma. These cells do provide surveillance and also permi作者: 爭議的蘋果 時間: 2025-3-28 17:36 作者: Hirsutism 時間: 2025-3-28 19:23
https://doi.org/10.1007/978-3-031-43415-0plored the use of T-cell immunotherapy (IT) to treat BTs in an extensive series of preclinical studies and, more recently, in clinical trials. Theoretically, the existence of the blood-brain barrier (BBB) and the lack of a lymphatic drainage system in the brain would impede the ability to elicit an 作者: FAZE 時間: 2025-3-28 22:57
Efficient Hyperdimensional Computing .. The growth and expansion of tumor cells throughout normal brain neuropil often cannot be contained without destroying normal brain tissue. Immunotherapy (IT) strategies became of interest to neuro-oncology researchers, because regeneration of normal brain is considered limited, at best, and beca作者: INCH 時間: 2025-3-29 05:22
Danai Koutra,Claudia Plant,Francesco Bonchiadoptive transfer of autologous cancer Ag-specific effector T-lymphocytes to treat individuals with progressing cancer. The use of this approach for the treatment of brain malignancy is described. The rationale is that the multiple genetic defects accumulating in cells during malignant transformatio作者: FLAX 時間: 2025-3-29 10:01 作者: 人充滿活力 時間: 2025-3-29 11:59 作者: 賠償 時間: 2025-3-29 19:14
Knowledge-Driven Active Learningients with glioblastoma multiforme (GBM) have an estimated 2-yr survival of less than 20% .. Leptomeningeal carcinomatosis carries an estimated mean survival of 2–3 months .. Localized RT techniques, such as brachytherapy and stereotactic radiosurgery, often fail to prevent disease progression at th作者: 朝圣者 時間: 2025-3-29 21:45
Danai Koutra,Claudia Plant,Francesco Bonchicells. Several adhesion molecules that are downregulated after completion of fetal brain development are re-expressed in neoplasms of the nervous system. The crucial role played by adhesion molecules during neural development is repeated during glioma invasion ..作者: Foreknowledge 時間: 2025-3-30 01:56 作者: 驚奇 時間: 2025-3-30 05:19 作者: Infusion 時間: 2025-3-30 11:58 作者: 迎合 時間: 2025-3-30 13:19 作者: FECK 時間: 2025-3-30 16:47
Current Therapy for Primary Brain Tumorsalignant brain tumors (BTs) have not kept abreast. Malignant astrocytoma is the most frequent primary BT in adults, and accounts for 2% of all cancers in this population .. The incidence of malignant astrocytoma varies considerably with age. For glioblastoma multiforme (GBM), it ranges from 0.2/100,作者: 現(xiàn)存 時間: 2025-3-30 23:15
Immunostimulation and Immunomodulation of Brain Tumorsent experimental evidence suggests that, despite the anatomical segregation of the brain from the general circulation by the blood-brain barrier (BBB) and lack of discrete lymphoid tissue, there are immunocompetent cells within the brain parenchyma. These cells do provide surveillance and also permi作者: 木訥 時間: 2025-3-31 01:30
